In June 2026, Sciwind Biosciences reported Phase 2 SLIMMER-UP-SWITCH trial data from China showing subcutaneous ecnoglutide achieved 12.8% weight loss versus 9.5% for semaglutide at 20 weeks, 35% greater (163 patients).

Overview Debates Related claims Topics Sources

The U.S. Treasury Department proposed adding biotechnology to the COINS Act list of sensitive restricted industries, alongside semiconductors, artificial intelligence, and quantum computing

Western pharmaceutical companies have invested tens of billions of dollars in Chinese biotechnology companies and licensing agreements to bolster their drug development pipelines

The U.S. Treasury Department cited national security concerns that American investments in Chinese biotech could be used to create biological weapons, develop brain-computer interfaces for surveillance, or cause U.S. supply chain overdependence

On October 22, 2026, the U.S. Treasury Department proposed updated rules for implementing the Comprehensive Outbound Investment National Security (COINS) Act of 2025 to restrict U.S. investment in the Chinese biotechnology sector

The U.S. Treasury Department's proposed COINS Act regulations would require U.S. investors to notify the government regarding certain biotech transactions in China and prohibit others entirely, subjecting violators to civil penalties and divestment

The U.S. Treasury Department's proposed restrictions cover equity interest acquisitions, debt financing, joint ventures, brain-computer interfaces, biomanufacturing equipment, and life sciences tools involving Chinese entities

The U.S. Treasury Department proposal defines prohibited biotech technologies to include small molecules, polymers, vaccines, blood components, allergenics, cell and gene therapies, and monoclonal antibodies or other recombinant therapeutic proteins

Study authors proposed bariatric surgery serve as a first-line treatment for clinical obesity, but as a second-line risk-reduction option for preclinical obesity as pharmacotherapy expands.

Clinical obesity prevalence among metabolic bariatric surgery candidates varied across international centers, ranging from 62.7% in the Brazilian cohort to 79.3% in the United Kingdom cohort.

Mean body mass index and distribution across BMI categories (<40, 40-49, and ≥50) did not differ significantly between clinical and preclinical obesity groups within surgical centers.

Study authors noted bariatric surgery in clinical obesity may offer faster economic returns due to reduced post-operative complications, decreased medication use, and fewer hospitalizations.

Bariatric surgery patients with clinical obesity lost modestly less weight post-surgery, trailing preclinical obesity patients by 2 to 4 percentage points in several study cohorts at 12 and 24 months.

Study authors stated bariatric surgery for preclinical obesity should be evaluated as a preventive intervention with longer time horizons and distinct cost-effectiveness thresholds.

Study authors suggested health systems with limited surgical capacity prioritize metabolic bariatric surgery for patients demonstrating clinical obesity-related organ dysfunction.

A Lancet Diabetes & Endocrinology Commission led by Dr. Francesco Rubino in January 2025 proposed separating clinical obesity from preclinical obesity based on organ dysfunction.

Investigators evaluated 2,316 adult gastric bypass and sleeve gastrectomy patients from centers in London, Barcelona, Lille, and São Paulo using the Lancet Diabetes & Endocrinology framework.

Patients with clinical obesity experienced higher baseline American Society of Anesthesiologists surgical risk classifications across all four international study cohorts compared to preclinical obesity patients.

In the French cohort analyzed in the study, major 30-day post-operative complications occurred in 4.0% of clinical obesity patients compared to 1.1% of preclinical obesity patients.

A JAMA Network Open study of 2,316 adults undergoing metabolic bariatric surgery between 2014 and 2025 found that 73.8% (1,709 patients) met criteria for clinical obesity.

A post hoc analysis of 1,902 women by menopausal status showed CagriSema produced 26.7% weight loss in premenopausal, 24.8% in perimenopausal, and 23.1% in postmenopausal women at 68 weeks, versus approximately 2% for placebo